97431f78-eea7-4799-8493-0ea4164a432b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- KRAS_SIGNALING_DN+0.400
- APICAL_SURFACE+0.300
- INFLAMMATORY_RESPONSE+0.300
- MYOGENESIS+0.300
- APICAL_JUNCTION+0.200
- COAGULATION+0.200
Top 10 suppressed
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V1-0.500
- ANDROGEN_RESPONSE-0.400
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V2-0.400
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.300
- DNA_REPAIR-0.200
- MTORC1_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9075936e-cc58-4740-abf4-1c733abb3d9f | — | — | 0.898 |
| 2 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.896 |
| 3 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.891 |
| 4 | 23849071-df2e-4421-b91d-90f66ec2c162 | — | — | 0.881 |
| 5 | c5e09ad2-1f0b-4ea3-9565-a1664f1bb468 | — | — | 0.875 |
| 6 | R101 | — | — | 0.874 |
| 7 | SRR1468574 | GTEX | — | 0.872 |
| 8 | SJEPD029_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.869 |
| 9 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.869 |
| 10 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |